This month, a large clinical study was published in the recognised American scientific journal WOUNDS. The study shows that a novel Micropore Particle Technology (MPPT), when used in the healing of complicated wounds, will reduce by 60% the time to rid the wound of the complicating factors and steer it onto the path of optimal healing. It also shows that patients hospitalised due to wounds can be discharged 30% sooner.The technology removes wound infections without the use of antibiotics. Consequently, it is able to remove antibiotic resistant infections from wounds.

Annually, the NHS spends £5.3 billion on direct wound care. The first product resulting from this new technology, Acapsil, can save 21% of those costs, potentially allowing the NHS to free up £1.1 bn annually for other purposes. These calculations do not take into account the additional benefits of the reduced risks of complications or the wound becoming chronic. Nor do they consider the advantages to the patients who can resume normal life, or the reduced use of antibiotics; we can preserve the remaining effective antibiotics as last resort for other diseases and avoid creating new resistance.

The wounds and ulcers in the study were all severe and needed hospitalisation and the intervention of a consultant.

Wounds constitute a key point of entry for infections to enter the rest of the body. The technology will, therefore, have positive implications beyond wound healing, as it will prevent sepsis or infections spreading to internal organs.

“Acapsil is simple but forceful. Indirectly, it supports the patient’s own immune system and enables it to progress the wound towards healing,” explain the joint managing directors of Willingsford Ltd., Frank and Jeanette Sams-Dodd who have dedicated the past nine years to the development of Acapsil. “The immune system of the individual patient knows best what needs to be done in order to heal a wound. If the wound will not heal, it is because the immune system is being inhibited. By cancelling this inhibition, the immune system can take control and push the wound towards closure;”

They go on: “We will over the coming years experience a change in patient’s expectations of how their complicated wounds will heal and close, instead of just being managed – as is often the case at the moment. This progress will have enormous socio-economic impact. Family breadwinners need not lose their jobs. The middle-aged and elderly will be able to live unaided or independently for much longer, as wounds and ulcers often have a disabling impact on lives.”

Acapsil was approved across the entire EU in 2016. It has since been evaluated by the NHS at University Hospital Bristol. Their evaluation confirmed the findings of the larger comparative clinical study published today.

Read the article in WOUNDS

Southampton, UK, 22 May 2017 – Press Release

This press release contains forward-looking statements about Willingsford Ltd. and the product, Acapsil. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that Acapsil and the revenues generated from Acapsil may be affected by competition; unexpected new data; safety and technical issues; clinical trials not being completed in a timely manner, not confirming previous results, or not achieving the intended clinical endpoints; pre-clinical trials not predicting future results; label expansion requests or filings not being submitted in a timely manner; regulatory approval being delayed or not received; or manufacturing and supply issues. The potential for Acapsil may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the development and commercialisation of pharmaceutical products and medical devices.